Publications by authors named "M Cruz Fernandez-Espartero"
Article Synopsis
- The study aimed to analyze gender differences and the impact of time since disease onset in patients with ankylosing spondylitis (AS) using data from the Spanish Registry of spondyloarthritis (REGISPONSER).
- Researchers evaluated various aspects of 1514 AS patients, including demographics, clinical activity, and structural damage through standardized assessments like the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
- Results indicated that men had an earlier onset and longer disease duration, while women showed higher BASDAI scores and familial patterns, highlighting significant gender-based clinical implications in AS management.
Objectives: To estimate the rate of demyelinating diseases in patients with rheumatic diseases treated with tumor necrosis factor (TNF) antagonists and to describe the cases reported to 3 different pharmacovigilance sources.
Methods: All confirmed cases of demyelinating disease, optic neuritis, and multiple sclerosis (MS) in patients with rheumatic diseases treated with TNF-antagonists were reviewed from 3 different sources: (1) the Spanish Registry of biological therapies in rheumatic diseases (BIOBADASER); (2) the Spanish Pharmacovigilance Database of Adverse Drug Reactions (FEDRA); and (3) a systematic review (PubMed, EMBASE, and the Cochrane Library). In BIOBADASER, the incidence rate per 1000 patients was estimated with a 95% confidence interval (95%CI).
[Treatment of refractory anterior diffuse scleritis with infliximab].
Arch Soc Esp Oftalmol
August 2004
Case Report: A 48-year old woman diagnosed with rheumatoid arthritis 10 years previously, developed severe anterior scleritis in the right eye (RE) refractory to conventional treatment. The patient was treated with 3 intravenous doses of Infliximab achieving complete remission of the scleral inflammation within four weeks.
Discussion: The use of Infliximab, a blocker of tumour necrosis factor (TNFalpha) could be an alternative approach to the management of refractory scleritis, but further long-term investigations would be necessary to evaluate their safety and efficacy.
Methotrexate-induced nephrogenic diabetes insipidus: first case report.
Rheumatology (Oxford)
February 2002